{"_buckets": {"deposit": "41221f44-ad70-4f48-ab42-7ebf3ade2f69"}, "_deposit": {"id": "2003747", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "2003747"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:02003747", "sets": []}, "author_link": [], "control_number": "2003747", "item_1615768549627": {"attribute_name": "\u51fa\u7248\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_9_biblio_info_6": {"attribute_name": "\u66f8\u8a8c\u60c5\u5831", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2022-08", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "553", "bibliographicPageStart": "547", "bibliographicVolumeNumber": "84", "bibliographic_titles": [{"bibliographic_title": "Nagoya Journal of Medical Science", "bibliographic_titleLang": "en"}]}]}, "item_9_description_4": {"attribute_name": "\u5185\u5bb9\u8a18\u8ff0", "attribute_value_mlt": [{"subitem_description": "Although the Cockcroft-Gault equation is still used for the dose adjustment of many drugs that have been approved prior to creatinine standardization, the clinical impact of standardized creatinine in the dose adjustment of capecitabine is poorly understood. We focused on patients with borderline renal function and evaluated the tolerability and safety of capecitabine in patients who received capecitabine plus oxaliplatin (Cape-Ox). We retrospectively identified patients with resected colorectal cancer who had received adjuvant therapy with Cape-Ox regimen. Creatinine clearance (CrCL) was calculated by the Cockcroft\u2013Gault equation with standardized creatinine measured using enzymatic methods, and adjusted CrCL was estimated by adding 0.2 (mg/dL) to the serum creatinine in the equation. We defined patients with \u201cpseudo-normal\u201d renal function as those who had an adjusted CrCL of \u226450 mL/min in patients with normal renal function (CrCL \u003e50 mL/min). We evaluated the tolerability and grade 2 or severer adverse events of capecitabine treatment. One hundred four patients had normal and 10 had impaired renal function (CrCL \u003c50 mL/min). Among the 104 patients with normal renal function, 23 (22.1%) had pseudo-normal renal function. Seventeen patients completed the eight cycles of Cape-Ox therapy without treatment delay or dose reduction, and all of them had truly normal renal function. The patients with pseudo-normal renal function were more likely to have grade 2 or severer thrombocytopenia than those with truly normal renal function. We should recognize correctly the clinical impact of standardized creatinine in the treatment of borderline renal function with Cape-Ox regimen in patients.", "subitem_description_language": "en", "subitem_description_type": "Abstract"}]}, "item_9_identifier_registration": {"attribute_name": "ID\u767b\u9332", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.18999/nagjms.84.3.547", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_publisher_32": {"attribute_name": "\u51fa\u7248\u8005", "attribute_value_mlt": [{"subitem_publisher": "Nagoya University Graduate School of Medicine, School of Medicine", "subitem_publisher_language": "en"}]}, "item_9_relation_43": {"attribute_name": "\u95a2\u9023\u60c5\u5831", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/843.html", "subitem_relation_type_select": "URI"}}]}, "item_9_rights_12": {"attribute_name": "\u6a29\u5229", "attribute_value_mlt": [{"subitem_rights": "Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International", "subitem_rights_language": "en", "subitem_rights_resource": "http://creativecommons.org/licenses/by-nc-nd/4.0/"}]}, "item_9_source_id_7": {"attribute_name": "\u53ce\u9332\u7269\u8b58\u5225\u5b50", "attribute_value_mlt": [{"subitem_source_identifier": "0027-7622", "subitem_source_identifier_type": "PISSN"}, {"subitem_source_identifier": "2186-3326", "subitem_source_identifier_type": "EISSN"}]}, "item_access_right": {"attribute_name": "\u30a2\u30af\u30bb\u30b9\u6a29", "attribute_value_mlt": [{"subitem_access_right": "open access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_abf2"}]}, "item_creator": {"attribute_name": "\u8457\u8005", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Ito, Ayaka", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Ichikawa, Kazuya", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Miyazaki, Masayuki", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Sagara, Atsunobu", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Motegi, Toshiki", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Ando, Yuichi", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Senzaki, Koji", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Nagai, Taku", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Yamada, Kiyofumi", "creatorNameLang": "en"}]}]}, "item_files": {"attribute_name": "\u30d5\u30a1\u30a4\u30eb\u60c5\u5831", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_access", "date": [{"dateType": "Available", "dateValue": "2022-09-06"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "07_Ito.pdf", "filesize": [{"value": "437 KB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_5", "mimetype": "application/pdf", "size": 437000.0, "url": {"objectType": "fulltext", "url": "https://nagoya.repo.nii.ac.jp/record/2003747/files/07_Ito.pdf"}, "version_id": "01a1855d-7178-4291-9da8-2471963cf704"}]}, "item_keyword": {"attribute_name": "\u30ad\u30fc\u30ef\u30fc\u30c9", "attribute_value_mlt": [{"subitem_subject": "capecitabine", "subitem_subject_scheme": "Other"}, {"subitem_subject": "creatinine clearance", "subitem_subject_scheme": "Other"}, {"subitem_subject": "renal function", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "\u8a00\u8a9e", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Clinical impact of standardized creatinine on dose adjustment of capecitabine", "item_titles": {"attribute_name": "\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_title": "Clinical impact of standardized creatinine on dose adjustment of capecitabine", "subitem_title_language": "en"}]}, "item_type_id": "40001", "owner": "1", "path": ["499/508/509/1662337921058"], "permalink_uri": "https://doi.org/10.18999/nagjms.84.3.547", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2022-09-05"}, "publish_date": "2022-09-05", "publish_status": "0", "recid": "2003747", "relation": {}, "relation_version_is_last": true, "title": ["Clinical impact of standardized creatinine on dose adjustment of capecitabine"], "weko_shared_id": -1}